IPO registrations (S-1, F-1) · Registrants
Bio Green Med Solution, Inc.
- SEC CIK
- 1130166 · filings on EDGAR ↗
- Name on the registration
- Cyclacel Pharmaceuticals, Inc.
- Former names
- Cyclacel Pharmaceuticals, Inc. (2006–2025); XCYTE THERAPIES INC (2000–2006)
- Registration
- Form S-1, first filed 2000-12-22, last 2025-07-31; 14 initial registrations, 18 amendments
- Outcome
- Final prospectus filed 2004-03-17; declared effective 2006-07-14; withdrawal requested 2001-12-03
- Industry (SIC)
- Wholesale-Durable Goods, NEC 5099
- Incorporated in
- DE
- Business address
- 200 CONNELL DRIVE, SUITE 1500, Berkeley Heights, NJ 07922
- EIN
- 91-1766850
- Ticker
- BGMS, BGMSP (Nasdaq, OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Bio Green Med Solution, Inc. on the corporate pages
On this site
- Form D issuer: Cyclacel Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- SEC filer: Bio Green Med Solution, Inc. EXACT (CIK (EXACT))
- Person page: James E Flynn Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther))
Filings 74
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2000-12-22 | S-1 | S-1 (registration) | XCYTE THERAPIES INC | 0000891020-00-002205 ↗ |
| 2001-12-03 | RW | RW (withdrawal request) | XCYTE THERAPIES INC | 0000891020-01-500347 ↗ |
| 2003-10-10 | S-1 | S-1 (registration) | XCYTE THERAPIES INC | 0001193125-03-060474 ↗ |
| 2003-11-21 | S-1/A | S-1/A (amendment) | XCYTE THERAPIES INC | 0001193125-03-085295 ↗ |
| 2004-02-17 | S-1/A | S-1/A (amendment) | XCYTE THERAPIES INC | 0001193125-04-023989 ↗ |
| 2004-03-03 | S-1/A | S-1/A (amendment) | XCYTE THERAPIES INC | 0001193125-04-033201 ↗ |
| 2004-03-09 | S-1/A | S-1/A (amendment) | XCYTE THERAPIES INC | 0001193125-04-036476 ↗ |
| 2004-03-16 | S-1/A | S-1/A (amendment) | XCYTE THERAPIES INC | 0001193125-04-042728 ↗ |
| 2004-03-17 | 424B4 | 424B4 (final prospectus) | XCYTE THERAPIES INC | 0001193125-04-043602 ↗ |
| 2004-10-07 | S-1 | S-1 (registration) | XCYTE THERAPIES INC | 0001193125-04-168220 ↗ |
| 2004-10-21 | S-1/A | S-1/A (amendment) | XCYTE THERAPIES INC | 0001193125-04-174775 ↗ |
| 2004-10-29 | S-1/A | S-1/A (amendment) | XCYTE THERAPIES INC | 0001193125-04-181019 ↗ |
| 2006-07-14 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-06-000749 ↗ |
| 2007-02-12 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-07-000597 ↗ |
| 2007-12-20 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-07-005035 ↗ |
| 2010-06-11 | RW | RW (withdrawal request) | Cyclacel Pharmaceuticals, Inc. | 0000950123-10-057561 ↗ |
| 2010-06-11 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0000950123-10-057563 ↗ |
| 2010-06-18 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0000950123-10-059178 ↗ |
| 2010-06-22 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-10-001892 ↗ |
| 2010-06-22 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-10-001895 ↗ |
| 2010-11-05 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0000950123-10-101807 ↗ |
| 2010-11-29 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0000950123-10-109295 ↗ |
| 2010-12-06 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-10-003452 ↗ |
| 2011-04-26 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-11-001169 ↗ |
| 2011-06-02 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-11-001714 ↗ |
| 2011-06-02 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-11-001717 ↗ |
| 2011-06-02 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-11-001718 ↗ |
| 2012-04-26 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-12-001180 ↗ |
| 2012-04-26 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-12-001187 ↗ |
| 2012-04-26 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-12-001188 ↗ |
| 2012-04-26 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-12-001190 ↗ |
| 2012-12-26 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001104659-12-086052 ↗ |
| 2013-01-11 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001104659-13-002089 ↗ |
| 2013-01-16 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-13-000201 ↗ |
| 2013-04-22 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-13-001099 ↗ |
| 2013-04-29 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-13-001176 ↗ |
| 2013-04-29 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-13-001178 ↗ |
| 2013-04-29 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-13-001181 ↗ |
| 2013-04-29 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-13-001183 ↗ |
| 2013-04-29 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-13-001201 ↗ |
| 2016-06-08 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-16-004851 ↗ |
| 2017-05-26 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001571049-17-005444 ↗ |
| 2017-06-30 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001571049-17-006442 ↗ |
| 2017-07-06 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001571049-17-006523 ↗ |
| 2017-07-17 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001571049-17-006728 ↗ |
| 2017-07-18 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-17-001937 ↗ |
| 2017-07-19 | S-1MEF | S-1MEF (added securities) | Cyclacel Pharmaceuticals, Inc. | 0001571049-17-006795 ↗ |
| 2017-07-20 | 424B4 | 424B4 (final prospectus) | Cyclacel Pharmaceuticals, Inc. | 0001571049-17-006835 ↗ |
| 2017-07-21 | 424B4 | 424B4 (final prospectus) | Cyclacel Pharmaceuticals, Inc. | 0001571049-17-006854 ↗ |
| 2019-06-21 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-19-001406 ↗ |
| 2020-03-13 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001104659-20-033221 ↗ |
| 2020-04-14 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001104659-20-046445 ↗ |
| 2020-04-20 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-20-000791 ↗ |
| 2020-04-22 | 424B4 | 424B4 (final prospectus) | Cyclacel Pharmaceuticals, Inc. | 0001104659-20-049790 ↗ |
| 2023-09-13 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-23-002656 ↗ |
| 2024-01-19 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-005261 ↗ |
| 2024-02-08 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-011776 ↗ |
| 2024-02-13 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-24-000423 ↗ |
| 2024-03-22 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-037954 ↗ |
| 2024-04-19 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-049518 ↗ |
| 2024-04-25 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-051334 ↗ |
| 2024-04-29 | RW | RW (withdrawal request) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-054177 ↗ |
| 2024-05-06 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-057546 ↗ |
| 2024-05-13 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-24-001518 ↗ |
| 2024-10-09 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-107090 ↗ |
| 2024-11-07 | RW | RW (withdrawal request) | Cyclacel Pharmaceuticals, Inc. | 0001104659-24-115099 ↗ |
| 2025-04-25 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001829126-25-002940 ↗ |
| 2025-04-29 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-25-001292 ↗ |
| 2025-07-24 | S-1 | S-1 (registration) | Cyclacel Pharmaceuticals, Inc. | 0001641172-25-020764 ↗ |
| 2025-07-25 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-25-002364 ↗ |
| 2025-07-31 | S-1/A | S-1/A (amendment) | Cyclacel Pharmaceuticals, Inc. | 0001641172-25-021610 ↗ |
| 2025-08-04 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-25-002470 ↗ |
| 2025-09-11 | EFFECT | EFFECT (declared effective) | Cyclacel Pharmaceuticals, Inc. | 9999999995-25-002922 ↗ |
| 2026-10-08 | EFFECT | EFFECT (declared effective) | Bio Green Med Solution, Inc. | 9999999995-26-003182 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| MARXE AUSTIN W & GREENHOUSE DAVID M | TenPercentOwner | 35 | 2006–2011 | ||
| Banham John Michael Middlecott | Director | 18 | 2006–2020 | ||
| Chiao Judy | Officer | V.P., Clin. Dev. & reg. Aff.; V.P., Clin. Dev. & Reg. Aff; V.P., Clin. Dev. & Reg. Aff. | 18 | 2006–2019 | |
| Jackson Robert | Officer | S.V.P. & Chief Scientific Offi | 3 | 2006 | |
| McBarron Paul | Director,Officer | E.V.P.,Finance,C.F.O. & C.O.O.; EVP, Finance, CFO, COO; E.V.P., Finance & C.O.O.; E. VP, Fin, CFO and COO; E.V.P., Fin, C.F.O. & C.O.O.; See Remarks | 22 | 2006–2023 | |
| McVie John Gordon | Director | 4 | 2006–2008 | ||
| Rombotis Spiro | Director,Officer | President and C.E.O.; President and CEO; President & C.E.O.; President & CEO | 46 | 2006–2023 | |
| UPRICHARD DAVID C | Director | 21 | 2006–2020 | ||
| Westwood Robert | Officer | V.P., Chem. & Preclin. Dev. | 3 | 2006 | |
| HENNEY CHRISTOPHER S | Director | 18 | 2006–2023 | ||
| SPIEGELMAN DANIEL K | Director | 7 | 2006–2012 | ||
| Womelsdorf Dr John Francis | Officer | VP, Business Development | 9 | 2006–2008 | |
| DELEAGE JEAN | Other | 1 | 2006 | ||
| Legault Pierre | Director | 3 | 2007–2008 | ||
| Reyes Gregory | Officer | Senior VP, Research | 4 | 2007–2008 | |
| Collins William | Officer | General Manager | 4 | 2007–2008 | |
| MORGAN STANLEY | TenPercentOwner | 25 | 2008–2009 | ||
| DEERFIELD CAPITAL LP | TenPercentOwner | 3 | 2008 | ||
| DEERFIELD MANAGEMENT CO /NY | TenPercentOwner | 3 | 2008 | ||
| Deerfield Special Situations Fund International LTD | TenPercentOwner | 3 | 2008 | ||
| Deerfield Special Situations Fund, L.P. | TenPercentOwner | 3 | 2008 | ||
| Flynn James E | TenPercentOwner; TenPercentOwnerOther | 3 | 2008 | person page Fuzzy | |
| Bacopoulos Nicholas G | Director | 10 | 2008–2016 | ||
| Sosnowski Robert Edward | Officer | VP, Marketing & Sales; VP, Sales & Marketing | 6 | 2008–2011 | |
| Hradsky Gregory T. | Director | 11 | 2011–2021 | ||
| Sems Lloyd | Director | 13 | 2011–2022 | ||
| BARKER SAM L | Director | 14 | 2014–2023 | ||
| DART KENNETH BRYAN | TenPercentOwner | 3 | 2015–2020 | ||
| Eastern Capital LTD | TenPercentOwner | 3 | 2015–2020 | ||
| Portfolio Services Ltd. | TenPercentOwner | 3 | 2015–2020 | ||
| TANG CAPITAL MANAGEMENT LLC | TenPercentOwner | 2 | 2017 | ||
| TANG CAPITAL PARTNERS LP | TenPercentOwner | 2 | 2017 | ||
| TANG KEVIN C | TenPercentOwner | 2 | 2017 | ||
| Spiegel Robert J. | Director | 7 | 2018–2023 | ||
| Kirschbaum Mark | Officer | Chief Medical Officer | 5 | 2020–2023 | |
| Walker Karin L | Director | 5 | 2020–2023 | ||
| SCHWARTZ BRIAN | Director; Director,Officer | Interim Chief Medical Officer | 6 | 2020–2024 | |
| Ferguson Kenneth M. | Director | 4 | 2022–2023 | ||
| Lazar David E. | Director,Officer; Officer,TenPercentOwner; TenPercentOwner | Chief Executive Officer; Interim CEO | 4 | 2025 | |
| NATAN DAVID | Director | 3 | 2025 | ||
| Ben-Tzvi Avraham | Director | 2 | 2025 | ||
| Chong Kwang Fock | Director | 1 | 2025 | ||
| Doris Wong Sing Ee | Director,Officer,TenPercentOwner | Chief Executive Officer | 2 | 2025 | |
| Kiu Cu Seng | Director,Officer | CFO and Secretary; Chief Financial Officer | 2 | 2025 | |
| Laurduraj Inigo Angel | Director | 1 | 2025 | ||
| Nair Krishnan Satis Waran | Director | 1 | 2025 | ||
| SURIA SUKSES ENGINEERING SDN BHD | Other; TenPercentOwner | 2 | 2025 | ||
| Tan Kok Hui | Other; TenPercentOwner | 2 | 2025 | ||
| Ho Jien Shiung | Other; TenPercentOwner | 2 | 2025 | ||
| Ho Kee Wee | Other; TenPercentOwner | 2 | 2025 | ||
| Kua Khai Loon | TenPercentOwner | 7 | 2025 | ||
| Ong Yee Lung | TenPercentOwner | 6 | 2025 | ||
| Yap Kim Choy | TenPercentOwner | 8 | 2025 | ||
| FITTERS Diversified Berhad | TenPercentOwner | 6 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-03-25 | Cyclacel Pharmaceuticals, Inc. | Biotechnology | $1,000,000 | $1,000,000 | 4 | 1 |
| 2025-02-14 | Cyclacel Pharmaceuticals, Inc. | Biotechnology | $25,000,000 | $0 | 1 | 1 |
| 2025-02-14 | Cyclacel Pharmaceuticals, Inc. | Biotechnology | $0 | $0 | 1 | 1 |
| 2024-11-26 | Cyclacel Pharmaceuticals, Inc. | Biotechnology | $2,062,112 | $2,062,112 | 1 | 1 |
| 2024-05-17 | Cyclacel Pharmaceuticals, Inc. | Biotechnology | $8,000,000 | $8,000,000 | 1 | 1 |
| 2021-01-04 | Cyclacel Pharmaceuticals, Inc. | Biotechnology | $7,000,000 | $7,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.